Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

This year, the companies got the potential billion-seller eczema drug Dupixent (dupilumab ... is researching medicines based around low molecular weight proteins called Anticalins.

these evidence support a therapeutic approach based on the selection of a molecular target in a shared area of the inflammatory cascade located upstream in the T2 immunologic pathway. The European ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

Background: Dextromethorphan (DM), the d-isomer of the codeine analog levorphanol, is an active ingredient present in a variety of cough and cold remedies. Recently, data generated from a study in ...

Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...